

Hypothyroidism in Pregnancy Primary Care Guidance (INTERIM GUIDANCE WHILST TRUST PATHWAYS ARE BEING REVIEWED)

Inadequately treated maternal hypothyroidism during pregnancy is associated with increased maternal and foetal complications. Hypothyroidism (including subclinical hypothyroidism) occurs in about 2.5% of pregnancies.

SFHT adopt a shared care service between community midwives and the obstetric-endocrine clinic. Patients should be referred to the obstetric-endocrine clinic as soon pregnancy is confirmed.

For NUH patients; **most women with hypothyroidism can be managed in the community** and can receive monitoring and dose titration in Primary Care.

A patient information leaflet and alert card ([guidance for patients](#)) is available via the British Thyroid Foundation.

| Trimester | TSH (mU/L) |
|-----------------|------------|
| 1 st | <2.5 mU/l |
| 2 nd | <3mU/l |
| 3 rd | <3mU/l |

| | Process | Further information | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|--|--|--------------------------|--------------------|---------------|----------------|-------|---------------|---------|---------|---------------|-------|-------|---------------|--------|---------|---------------|----------|--------|-------------|--------|----------|---------------|--------|--------|-------------|--------|--------|---------------|----------|--------|---------------|----------|--------|-------------|--------|--------|---------------|--------|--------|-------------|--------|
| Pre-conception FOR ALL | Adjustment of the preconception levothyroxine dose with aim to keep TSH <2.5 mU/L . If opportunity arises, make a plan with patients so they can self-initiate an agreed increase in dose whilst they wait to see a GP and have TFT levels checked. | Refer patients with persistent clinical or sub-clinical hyperthyroidism (<0.35mU/L) to endocrine pre-conception as per NICE guidance. All women with clinical/sub-clinical pregestational thyrotoxicosis should be referred to endocrine pre-conception if possible. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Once pregnancy confirmed FOR ALL | <p>Increasing the levothyroxine dose is recommended as early as possible in pregnancy and if possible, should not wait until the booking appointment.</p> <p>Immediately on notification of pregnancy:</p> <ul style="list-style-type: none"> Arrange TFT's (specify pregnancy and gestation on ICE request to ensure correct gestational reference ranges are applied) and Immediately increase levothyroxine as per table opposite <u>whilst awaiting</u> up to date TFT results. <p>Advise patients to self-refer to midwifery services promptly.</p> <p>Initial TFT's will be undertaken by CMW with booking bloods if not already done by GP (usually at 8-10 weeks).</p> <p style="text-align: center;">Remember to specify pregnancy and gestation on ICE request.</p> | <table border="1"> <thead> <tr> <th rowspan="13" style="writing-mode: vertical-rl; transform: rotate(180deg);">Dose in micrograms (mcg)</th> <th>Pre-pregnancy dose</th> <th>Dose increase</th> <th>Resulting dose</th> </tr> </thead> <tbody> <tr><td>50mcg</td><td>12.5mcg (25%)</td><td>62.5mcg</td></tr> <tr><td>62.5mcg</td><td>12.5mcg (20%)</td><td>75mcg</td></tr> <tr><td>75mcg</td><td>25mcg (33.3%)</td><td>100mcg</td></tr> <tr><td>87.5mcg</td><td>25mcg (28.6%)</td><td>112.5mcg</td></tr> <tr><td>100mcg</td><td>25mcg (25%)</td><td>125mcg</td></tr> <tr><td>112.5mcg</td><td>25mcg (22.2%)</td><td>137mcg</td></tr> <tr><td>125mcg</td><td>25mcg (20%)</td><td>150mcg</td></tr> <tr><td>150mcg</td><td>27.5mcg (25%)</td><td>187.5mcg</td></tr> <tr><td>175mcg</td><td>37.5mcg (21%)</td><td>212.5mcg</td></tr> <tr><td>200mcg</td><td>50mcg (25%)</td><td>250mcg</td></tr> <tr><td>225mcg</td><td>50mcg (22.2%)</td><td>275mcg</td></tr> <tr><td>250mcg</td><td>50mcg (20%)</td><td>300mcg</td></tr> </tbody> </table> | Dose in micrograms (mcg) | Pre-pregnancy dose | Dose increase | Resulting dose | 50mcg | 12.5mcg (25%) | 62.5mcg | 62.5mcg | 12.5mcg (20%) | 75mcg | 75mcg | 25mcg (33.3%) | 100mcg | 87.5mcg | 25mcg (28.6%) | 112.5mcg | 100mcg | 25mcg (25%) | 125mcg | 112.5mcg | 25mcg (22.2%) | 137mcg | 125mcg | 25mcg (20%) | 150mcg | 150mcg | 27.5mcg (25%) | 187.5mcg | 175mcg | 37.5mcg (21%) | 212.5mcg | 200mcg | 50mcg (25%) | 250mcg | 225mcg | 50mcg (22.2%) | 275mcg | 250mcg | 50mcg (20%) | 300mcg |
| Dose in micrograms (mcg) | Pre-pregnancy dose | Dose increase | | Resulting dose | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 50mcg | 12.5mcg (25%) | | 62.5mcg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 62.5mcg | 12.5mcg (20%) | | 75mcg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 75mcg | 25mcg (33.3%) | | 100mcg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 87.5mcg | 25mcg (28.6%) | | 112.5mcg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 100mcg | 25mcg (25%) | | 125mcg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 112.5mcg | 25mcg (22.2%) | | 137mcg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 125mcg | 25mcg (20%) | | 150mcg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 150mcg | 27.5mcg (25%) | | 187.5mcg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 175mcg | 37.5mcg (21%) | | 212.5mcg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 200mcg | 50mcg (25%) | | 250mcg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 225mcg | 50mcg (22.2%) | | 275mcg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 250mcg | 50mcg (20%) | 300mcg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Management plan during pregnancy | <p>GP led management at NUH</p> <p>Referral to antenatal endocrine clinic is recommended for women:</p> <ul style="list-style-type: none"> with sub-clinical/clinical hyperthyroidism (not on levothyroxine), who are hypothyroid after thyroidectomy or radio-iodine treatment for thyrotoxicosis. <p>GP to:</p> <ul style="list-style-type: none"> Check TSH every 4-6 weeks until 20 weeks' gestation Check TSH once more at 28-30 weeks' gestation Titrate levothyroxine to achieve TSH as per laboratory gestational reference range. <p>If there are difficulties with management, ask CMW to refer to antenatal endocrine clinic (GP to provide up to date management information).</p> | <p>Antenatal Endocrine clinic led management at SFH</p> <p>Patient managed via shared care between CMW and obstetric-endocrine clinic.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Following delivery FOR ALL | <ul style="list-style-type: none"> Reduce to <u>pre-pregnancy dose</u> on next dose after pregnancy ends. If <u>not on replacement therapy pre-pregnancy</u>, reduce in 50mcg increments (stop if on ≤50mcg). If on levothyroxine preconception solely for TSH optimisation/sub-clinical hypothyroidism, levothyroxine should be stopped completely. Check TFTs 6 weeks after delivery for all women prescribed levothyroxine during pregnancy and adjust levothyroxine dose if required. | <p>Patients with thyroid antibodies are at greater risk of post-partum thyroiditis, usually presenting around 3-4 months post-partum with symptoms of hyperthyroidism followed by a period of hypothyroidism before returning to normal (usually within 1 year of birth). Consider further repeat TFT's if concerned.</p> <p>Post-partum thyroiditis Patient Information Leaflet Thyroid UK.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Anytime | Refer to antenatal endocrine clinic if there are concerns | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |